Perceptive Advisors LLC Sells 198,888 Shares of enGene Holdings Inc. (NASDAQ:ENGN)

Perceptive Advisors LLC cut its position in enGene Holdings Inc. (NASDAQ:ENGN) by 19.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 800,000 shares of the company’s stock after selling 198,888 shares during the period. Perceptive Advisors LLC owned about 1.81% of enGene worth $7,544,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BVF Inc. IL acquired a new position in shares of enGene in the 4th quarter valued at approximately $20,777,000. Logos Global Management LP boosted its stake in enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after purchasing an additional 400,000 shares during the period. Omega Fund Management LLC bought a new position in shares of enGene during the fourth quarter worth about $10,441,000. Janus Henderson Group PLC bought a new stake in enGene in the 1st quarter valued at approximately $17,095,000. Finally, SR One Capital Management LP bought a new stake in enGene in the 2nd quarter valued at approximately $4,715,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Trading Up 10.0 %

ENGN stock opened at $6.05 on Monday. The company’s 50-day simple moving average is $7.00 and its 200 day simple moving average is $10.74. enGene Holdings Inc. has a 52 week low of $4.42 and a 52 week high of $43.00. The company has a market capitalization of $267.20 million, a PE ratio of -3.52 and a beta of -0.68. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. As a group, sell-side analysts anticipate that enGene Holdings Inc. will post -1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ENGN. Morgan Stanley restated an “overweight” rating and set a $40.00 target price on shares of enGene in a report on Wednesday, September 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 target price on shares of enGene in a report on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, enGene has a consensus rating of “Buy” and an average price target of $33.67.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.